HRP20241574T1 - Metode za početak doziranja liječenja aripiprazolom - Google Patents

Metode za početak doziranja liječenja aripiprazolom Download PDF

Info

Publication number
HRP20241574T1
HRP20241574T1 HRP20241574TT HRP20241574T HRP20241574T1 HR P20241574 T1 HRP20241574 T1 HR P20241574T1 HR P20241574T T HRP20241574T T HR P20241574TT HR P20241574 T HRP20241574 T HR P20241574T HR P20241574 T1 HRP20241574 T1 HR P20241574T1
Authority
HR
Croatia
Prior art keywords
aripiprazole
depot formulation
patient
use according
oral
Prior art date
Application number
HRP20241574TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew HARLIN
Xiaofeng Wang
Yanlin Wang
Arash Raoufinia
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20241574(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20241574T1 publication Critical patent/HRP20241574T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
HRP20241574TT 2020-04-01 2021-04-01 Metode za početak doziranja liječenja aripiprazolom HRP20241574T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments
EP21720012.0A EP4125903B1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Publications (1)

Publication Number Publication Date
HRP20241574T1 true HRP20241574T1 (hr) 2025-01-31

Family

ID=75581573

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241574TT HRP20241574T1 (hr) 2020-04-01 2021-04-01 Metode za početak doziranja liječenja aripiprazolom

Country Status (16)

Country Link
US (6) US20230129919A1 (cg-RX-API-DMAC7.html)
EP (3) EP3941470A1 (cg-RX-API-DMAC7.html)
JP (4) JP7584535B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240165486A (cg-RX-API-DMAC7.html)
CN (3) CN115397420A (cg-RX-API-DMAC7.html)
AU (2) AU2021248212A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022018721A2 (cg-RX-API-DMAC7.html)
CA (3) CA3163321C (cg-RX-API-DMAC7.html)
ES (1) ES2995466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241574T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069157T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022012354A (cg-RX-API-DMAC7.html)
PL (1) PL4125903T3 (cg-RX-API-DMAC7.html)
TW (4) TWI865760B (cg-RX-API-DMAC7.html)
WO (2) WO2021201238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210633B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2024194955A1 (en) 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments

Also Published As

Publication number Publication date
BR112022018721A2 (pt) 2022-11-01
MX2022012353A (es) 2022-10-31
HUE069157T2 (hu) 2025-02-28
US20230129919A1 (en) 2023-04-27
KR20220161403A (ko) 2022-12-06
TWI906279B (zh) 2025-12-01
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
KR20240165486A (ko) 2024-11-22
AU2021248212A1 (en) 2022-12-01
CA3136727A1 (en) 2021-10-07
EP3941470A1 (en) 2022-01-26
MX2022012354A (es) 2022-10-31
EP4125903A1 (en) 2023-02-08
TWI865760B (zh) 2024-12-11
JP7584535B2 (ja) 2024-11-15
ES2995466T3 (en) 2025-02-10
US12691056B2 (en) 2026-07-28
WO2021201239A1 (en) 2021-10-07
CN119792290A (zh) 2025-04-11
US20240374506A1 (en) 2024-11-14
JP7891516B2 (ja) 2026-07-16
EP4125903B1 (en) 2024-10-09
JP2023520004A (ja) 2023-05-15
KR102732030B1 (ko) 2024-11-20
EP4467194A3 (en) 2025-01-08
AU2021245713A1 (en) 2022-12-01
PL4125903T3 (pl) 2025-02-03
JP2025176037A (ja) 2025-12-03
CA3163321A1 (en) 2021-10-07
JP7733000B2 (ja) 2025-09-02
US20220160621A1 (en) 2022-05-26
US20230225962A1 (en) 2023-07-20
TW202523329A (zh) 2025-06-16
EP4125903C0 (en) 2024-10-09
KR20220161402A (ko) 2022-12-06
TW202200141A (zh) 2022-01-01
WO2021201238A1 (en) 2021-10-07
BR112022018647A2 (pt) 2022-11-08
JP2023519425A (ja) 2023-05-10
CN115397420A (zh) 2022-11-25
US20260034053A1 (en) 2026-02-05
EP4467194A2 (en) 2024-11-27
CN115379842A (zh) 2022-11-22
CA3163321C (en) 2023-12-19
CA3212191A1 (en) 2021-10-07
US20260115131A1 (en) 2026-04-30
JP2025020306A (ja) 2025-02-12
TW202615022A (zh) 2026-04-16

Similar Documents

Publication Publication Date Title
Ciardiello et al. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
JP2018199733A5 (cg-RX-API-DMAC7.html)
JP2011511072A5 (cg-RX-API-DMAC7.html)
DK1390040T3 (da) Farmaceutisk præparat til anvendelse i hormonerstatningsterapi
JP2013509435A5 (cg-RX-API-DMAC7.html)
JP2023520004A5 (cg-RX-API-DMAC7.html)
IL95505A (en) Neuro-peptide containing erection-inducing compositions and use thereof
JP2004524278A5 (cg-RX-API-DMAC7.html)
RU2014105288A (ru) Способы и композиции для лечения астмы с использованием антител против il-13
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
HRP20030793B1 (hr) Parenteralni pripravak za rekonstituciju koji sadrži cox-2 inhibitor
US8388963B2 (en) Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof
ZA202210633B (en) Methods for dose initiation of aripiprazole treatments
EA200600200A1 (ru) Способ лечения синдрома отвыкания от зависимости
Himmelsbach et al. Studies on modification of the morphine abstinence syndrome by drugs
Greer et al. Bimekizumab-bkzx for the treatment of plaque psoriasis: A drug review
Song et al. Differential Involvement of Central and Peripheral Norepinephrine in the Central Lipopolysaccharide‐Induced Interleukin‐6 Responses in Mice
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
AU715260B2 (en) TNF receptor and steroid hormone in a combined therapy
JP2023500045A (ja) Stingアゴニストを用いたがんを処置する方法
Kissin et al. Does midazolam inhibit the development of acute tolerance to the analgesic effect of alfentanil?
MX2025012679A (es) Inicio de dosis para el tratamiento de la esquizofrenia o el trastorno bipolar i con aripiprazol
Salvi et al. VRDN-003, a full antagonist antibody to IGF-1R for thyroid eye disease (TED): Phase 1 results show potential for subcutaneous administration
JPS5927822A (ja) 医療用組成物及びこの組成物を有効成分とする抗炎症抗潰瘍用剤
Yoon et al. Synergistic antinociception of intrathecal sildenafil with clonidine in the rat formalin test